<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047783</url>
  </required_header>
  <id_info>
    <org_study_id>AB21002</org_study_id>
    <secondary_id>2021-002620-20</secondary_id>
    <nct_id>NCT05047783</nct_id>
  </id_info>
  <brief_title>Masitinib in Patients With Symptomatic Mild to Moderate COVID-19</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate the Anti-viral Efficacy of Masitinib in Patients With Symptomatic Mild to Moderate COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the anti-viral efficacy of 3 different dosages of&#xD;
      masitinib in patients with symptomatic mild to moderate COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to evaluate the virologic efficacy of masitinib plus Best Supportive&#xD;
      Care (BSC), with respect to placebo plus BSC in reducing viral shedding of SARS-CoV-2 in&#xD;
      patients with symptomatic mild to moderate COVID-19.&#xD;
&#xD;
      Patients will be randomized into one of the following treatment groups (all patients will&#xD;
      receive BSC):&#xD;
&#xD;
        1. Masitinib 3.0 mg/kg/day for 10 days versus corresponding placebo&#xD;
&#xD;
        2. Masitinib 3.0 mg/kg/day for 2 days then 4.5 mg/kg/day for 8 days versus corresponding&#xD;
           placebo&#xD;
&#xD;
        3. Masitinib 3.0 mg/kg/day for 2 days then 4.5 mg/kg/day for 2 days then 6.0 mg/kg/day for&#xD;
           6 days versus corresponding placebo Treatments will be administered for 10 days and&#xD;
           patients will be followed for 1 month. The treatment groups will be compared to pooled&#xD;
           placebo after unblinding.&#xD;
&#xD;
      Regarding Best Supportive Care, for patients with a score of 2 and 3 (ambulatory) on the&#xD;
      10-score WHO clinical progression scale, Best Supportive Care is best available therapy in&#xD;
      the country at the choice of the investigator excluding any antiviral treatment whether&#xD;
      indirect (Ribavirin, Hydroxychloroquine or Chloroquine) or direct (anti-polymerase or&#xD;
      antiprotease, including lopinavir/ritonavir fixed dose combination), other investigational&#xD;
      treatments for SARS-CoV-2, plasma from a person who recovered from COVID-19, monoclonal&#xD;
      antibody therapies and vaccine. For patients with a score of 4 and 5 (hospitalized) on the&#xD;
      10-score WHO clinical progression scale, Best Supportive Care is dexamethasone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-Blind, Placebo-Controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SARS-Cov-2 Viral Load at Day 10</measure>
    <time_frame>Baseline to Day 10</time_frame>
    <description>Time-weighted average change from baseline in viral shedding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SARS-Cov-2 Viral Load to post-baseline study days</measure>
    <time_frame>Baseline up to Day 28</time_frame>
    <description>Time-weighted average change from baseline in viral shedding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to negative RT-qPCR result</measure>
    <time_frame>Baseline up to Day 28</time_frame>
    <description>Time to negative RT-qPCR result in all tested samples with no subsequent positive RT-qPCR in any tested samples</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-CoV2 Infection</condition>
  <condition>Coronavirus Disease 2019</condition>
  <arm_group>
    <arm_group_label>Masitinib 3.0 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Masitinib 3.0 mg/kg/day for 10 days versus corresponding placebo (all patients will receive Best Supportive Care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Masitinib 4.5 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Masitinib 3.0 mg/kg/day for 2 days then 4.5 mg/kg/day for 8 days versus corresponding placebo (all patients will receive Best Supportive Care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Masitinib 6.0 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Masitinib 3.0 mg/kg/day for 2 days then 4.5 mg/kg/day for 2 days then 6.0 mg/kg/day for 6 days versus corresponding placebo (all patients will receive Best Supportive Care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arms associated with the three Experimental arms (all patients will receive Best Supportive Care) which will be pooled for analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Masitinib Mesylate</intervention_name>
    <description>3CL-protease inhibitor</description>
    <arm_group_label>Masitinib 3.0 mg/kg/day</arm_group_label>
    <arm_group_label>Masitinib 4.5 mg/kg/day</arm_group_label>
    <arm_group_label>Masitinib 6.0 mg/kg/day</arm_group_label>
    <other_name>Masitinib</other_name>
    <other_name>AB1010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        - Male or non-pregnant female with: A. Symptomatic ambulatory male or non-pregnant female&#xD;
        adult ≥ 18 years of age at time of enrolment with mild COVID-19 with score 2 or 3 of the&#xD;
        10-score WHO clinical progression scale OR B. Hospitalized male or non-pregnant female&#xD;
        adult ≥ 18 years of age at time of enrolment with COVID-19 with score 4 or 5 of the&#xD;
        10-score WHO clinical progression scale.&#xD;
&#xD;
          -  Symptoms consistent with COVID-19, as determined by investigator, with onset ≤5 days&#xD;
             before randomization&#xD;
&#xD;
          -  Positive test for COVID-19 ≤72 hours prior to randomization&#xD;
&#xD;
          -  Negative test for the IgG anti-SARS-CoV-2&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Any use of anti-viral medications up to 7 days before participating in the study&#xD;
&#xD;
          -  Receipt of plasma from a person who recovered from COVID-19 (convalescent plasma) any&#xD;
             time before participating in the study&#xD;
&#xD;
          -  Receipt of last recommended dose of a SARS-CoV-2 vaccine up to 30 days before&#xD;
             participating in the study&#xD;
&#xD;
          -  Receipt of a monoclonal antibodies up to 30 days before participating in the study.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume LAURICHESSE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Gabriel-Montpied, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Study Coordinator</last_name>
    <phone>+33(0)147200014</phone>
    <email>clinical@ab-science.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Intensive Care Unit, CHU Gabriel-Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Masitinib is under clinical investigation and has not yet been approved in any sought-after indication by any health authority worldwide. As such, there is no plan for data-sharing at this point in time.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

